---
title: "BIOTEST BIOTECH: The net profit for the year 2024 is 177 million yuan, a year-on-year increase of 65.74%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/229714983.md"
description: "According to the Zhitong Finance APP, BIOTEST BIOTECH released its performance preliminary report for the year 2024. During the reporting period, the company achieved operating revenue of 561 million yuan, a year-on-year increase of 26.80%; the net profit attributable to the parent company's owners was 177 million yuan, a year-on-year increase of 65.74%; the net profit attributable to the parent company's owners after deducting non-recurring gains and losses was 127 million yuan, a year-on-year increase of 59.35%; basic earnings per share were 1.68 yuan/share"
datetime: "2025-02-26T08:24:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/229714983.md)
  - [en](https://longbridge.com/en/news/229714983.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/229714983.md)
generator: "portal-rs"
---

# BIOTEST BIOTECH: The net profit for the year 2024 is 177 million yuan, a year-on-year increase of 65.74%

According to the Zhitong Finance APP, BIOTEST BIOTECH (688767.SH) released its performance preliminary report for the year 2024. During the reporting period, the company achieved operating revenue of 561 million yuan, a year-on-year increase of 26.80%; the net profit attributable to the parent company's owners was 177 million yuan, a year-on-year increase of 65.74%; the net profit attributable to the parent company's owners after deducting non-recurring gains and losses was 127 million yuan, a year-on-year increase of 59.35%; basic earnings per share were 1.68 yuan/share

### Related Stocks

- [688767.CN](https://longbridge.com/en/quote/688767.CN.md)

## Related News & Research

- [Rice farmers face losses as paddy prices drop](https://longbridge.com/en/news/298143455.md)
- [Canadian Solar highlights $3.5 billion energy storage backlog in investor deck](https://longbridge.com/en/news/297991668.md)
- [ION: High-recovery modular platform targets U.S. rare earth supply chain with strong economics](https://longbridge.com/en/news/298143562.md)
- [09:33 ETSurfshark launches beta tester program, inviting users to shape the future of cybersecurity](https://longbridge.com/en/news/298046143.md)
- [Fosun Pharma subsidiary Shanghai Fosun Pharmaceutical Industrial Development wins China approval for new Luvometinib use in adult NF1 tumors](https://longbridge.com/en/news/297890174.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**